RNA-sequencing reveals positional memory of multipotent mesenchymal stromal cells from oral and maxillofacial tissue transcriptomes

CURRENT STATUS: Under Review

Satoru Onizuka, Yasuharu Yamazaki, Sung-Joon Park, Takayuki Sugimoto, Yumiko Sone, Sebastian Sjöqvist, Michihiko Usui, Akira Takeda, Kenta Nakai, Keisuke Nakashima, Takanori Iwata

Satoru Onizuka
Kyushu Dental University

Yasuharu Yamazaki
Kitasato University School of Medicine

Sung-Joon Park
The University of Tokyo

Takayuki Sugimoto
Kitasato University School of Medicine

Yumiko Sone
Kitasato University School of Medicine

Sebastian Sjöqvist
Tokyo Women’s Medical University

Michihiko Usui
Kyushu Dental University

Akira Takeda
Kitasato University School of Medicine

Kenta Nakai
The University of Tokyo

Keisuke Nakashima
Kyushu Dental University

Takanori Iwata
Tokyo Ika Shika Daigaku Daigakin Ishigaku Sogo Kenkyuka

Corresponding Author
iwata.peri@tmd.ac.jp
Subject Areas

Epigenetics & Genomics

Keywords

Multipotent mesenchymal stromal cells, RNA-sequencing, HOX genes, maxillofacial bone, iliac bone, periodontal ligament
Background Multipotent mesenchymal stromal cells (MSCs) can be isolated from numerous tissues and are attractive candidates for therapeutic clinical applications due to their immunomodulatory and pro-regenerative capacity. Although the minimum criteria for defining MSCs have been defined, their characteristics are known to vary depending on their tissue of origin.

Results We isolated and characterized human MSCs from three different bones (ilium (I-MSCs), maxilla (Mx-MSCs) and mandibular (Md-MSCs)) and proceeded with next generation RNA-sequencing. Furthermore, to investigate the gene expression profiles among other cell types, we obtained RNA-seq data of human embryonic stem cells (ESCs) and several types of MSCs (periodontal ligament-derived MSCs, bone marrow-derived MSCs, and ESCs-derived MSCs) from the Sequence Reads Archive and analyze the transcriptome profile. We found that MSCs derived from tissues of the maxillofacial region, such as the jaw bone and periodontal ligament, were HOX-negative, while those derived from other tissues were HOX-positive. We also identified that MSX1, LHX8, and BARX1, an essential regulator of craniofacial development, were strongly expressed in maxillofacial tissue-derived MSCs. Although MSCs may be divided into two distinct groups, the cells originated from over the neck or not, on the basis of differences in gene expression profile, the expression patterns of all CD antigen genes were similar among different type of MSCs, except for ESCs.

Conclusions Our findings suggest that MSCs from different anatomical locations, despite meeting general characterization criteria, have remarkable differences in gene expression and positional memory. Although stromal cells from different anatomical sources are generally categorized as MSCs, their differentiation potential and biological functions vary. We suggested that MSCs may retain an original tissue memory about the developmental process, including gene expression profiles. This could have an important impact when choosing an appropriate cell source for regenerative therapy using MSCs.

Abstract

Background Multipotent mesenchymal stromal cells (MSCs) can be isolated from numerous tissues and are attractive candidates for therapeutic clinical applications due to their immunomodulatory and pro-regenerative capacity. Although the minimum criteria for defining MSCs have been defined, their characteristics are known to vary depending on their tissue of origin.

Results We isolated and characterized human MSCs from three different bones (ilium (I-MSCs), maxilla (Mx-MSCs) and mandibular (Md-MSCs)) and proceeded with next generation RNA-sequencing. Furthermore, to investigate the gene expression profiles among other cell types, we obtained RNA-seq data of human embryonic stem cells (ESCs) and several types of MSCs (periodontal ligament-derived MSCs, bone marrow-derived MSCs, and ESCs-derived MSCs) from the Sequence Reads Archive and analyze the transcriptome profile. We found that MSCs derived from tissues of the maxillofacial region, such as the jaw bone and periodontal ligament, were HOX-negative, while those derived from other tissues were HOX-positive. We also identified that MSX1, LHX8, and BARX1, an essential regulator of craniofacial development, were strongly expressed in maxillofacial tissue-derived MSCs. Although MSCs may be divided into two distinct groups, the cells originated from over the neck or not, on the basis of differences in gene expression profile, the expression patterns of all CD antigen genes were similar among different type of MSCs, except for ESCs.

Conclusions Our findings suggest that MSCs from different anatomical locations, despite meeting general characterization criteria, have remarkable differences in gene expression and positional memory. Although stromal cells from different anatomical sources are generally categorized as MSCs, their differentiation potential and biological functions vary. We suggested that MSCs may retain an original tissue memory about the developmental process, including gene expression profiles. This could have an important impact when choosing an appropriate cell source for regenerative therapy using MSCs.
biomaterials was shown to be effective in various animal models for repairing bony defects [21-23]. However, it
remains unclear which source of MSCs is the most suitable for bone regeneration.

The maxillofacial skeleton is derived from the cranial neural crest whereas the remainder of the skeleton
originates from the mesoderm [24, 25]. It is therefore fundamental to determine whether progenitor cells
originating from bone tissue derived from mesoderm can completely regenerate or repair maxillofacial bone.
Although MSCs derived from various tissue satisfy the international minimal defining criteria, these cells exhibit
different characteristics in terms of proliferation ability, differentiation potential, and gene expression profiles
[26-28]. Therefore, to investigate variations in differentiation abilities and gene expression patterns among
various types of MSCs, we performed differentiation assay and RNA-sequencing (RNA-seq) using next-generation
sequencing analysis. Our results suggest that MSCs derived from different types of tissue, especially the cells
originated from over the neck or not, have positional memories and varying gene expression profiles that may
influence their cellular characteristics.

Results

MSCs from different anatomical locations exhibit varying differentiation potential. First, to verify that
the cells used in this study have multipotency to differentiate into several cell types, we performed
differentiation assays (Figure 1 and Supplemental Figure 1). Alizarin red S staining showed that all types of MSCs
could differentiate into osteoblasts and form mineralized nodules, but the degree of mineralization was lower for
Mx-MSCs than for other MSCs (Figure 1A). Oil Red O and toluidine blue staining assay showed that I-MSCs had
the greatest potential for adipogenic and chondrogenic differentiation compared with Mx-MSCs and Md-MSCs
(Figure 1B and 1C). In the calcium content assay, I-MSCs and Md-MSCs produced more Ca than Mx-MSCs when
the cells were cultured in ODM for 4 weeks (Figure 1D). Moreover, Ca levels in I-MSCs were significantly higher
than in Mx-MSCs when the cells were cultured in ODM for 6 weeks (Figure 1D).

The general profile of RNA-seq data.

The Ion Proton system generated 31.5–52.8 million single-ended 50–200 bp reads from nine samples (Figure 2A).
Unmapped reads were reduced to less than 5% by removing low-quality reads. Genes with low expression
(fragment per kilobase of exon per million mapped fragments (FPKM) < 1.0) were removed from the three
groups, leaving a total of 12,676 genes. Most non-coding RNAs (long intergenic noncoding RNAs, microRNAs,
small nuclear RNAs, small nucleolar RNAs, and pseudogenes) had a FPKM <1 in all samples (Figure 2B). To verify
that the cells used in this study have specific MSC markers, we analyzed the gene expression profile of CD14,
CD45 (PTPRC), CD73 (NT5E), CD90 (THY1), and CD105 (ENG). RNA-seq data of human macrophage (MΦ) used as
control were obtained from the Sequence Reads Archive (DDBJ) accession number: SRA245718). In three types of
MSCs, the expression levels of CD73, CD90, and CD105, widely known as specific surface markers of MSCs, were
higher than those in MΦ. On the other hand, the three types of MSCs had little expression of CD14 and 45
(Figure 2C). Using genes expressed in at least one of the groups with FPKM ≥1, we detected 10 different gene
clusters in MSCs that exhibited distinct expression patterns (Figure 2D). The genes in each cluster were
significantly enriched by specific GO terms. For instance, GO terms associated with the cell cycle and cell
adhesion detected from cluster 7 consisted of genes up-regulated in Mx-MSCs compared with other MSCs, while
GO terms associated with cell migration detected from cluster 2 consisted of genes up-regulated in I-MSCs
compared with other MSCs. These results suggested that the cell growth and migration properties of each cell
type were different.

GO term enrichment analysis reveals differences between I-MSCs and Mx-/Md-MSCs.

To detect potential key regulators of each sample, we investigated DEGs between Mx-MSCs vs. I-MSCs, Md-MSCs
vs. I-MSCs, and Mx-MSCs vs. Md-MSCs, and identified 973, 365, and 602 DEGs, respectively (Figure 3A). To
investigate differences in skeletal development and endochondral and intramembranous ossification, GO term
enrichment analysis for I-MSC-specific DEGs was performed. A total of 140 DEGs were up-regulated in I-MSCs
compared with Mx- and Md-MSCs (U-DEGs) (Figure 3B). DAVID annotation of these DEGs revealed that most of
the top 10 enriched GO terms were involved in development. A total of 96 DEGs were down-regulated in I-MSCs

4
compared with Mx- and Md-MSCs (D-DEGs), and most of the top 10 enriched GO terms were also involved in development (Figure 3C). These results indicate that I-MSCs and Mx-/Md-MSCs are regulated by genes involved in development.

**Whole transcriptome analysis shows that MSCs derived from tissue in the maxillofacial region are HOX-negative.**

Based on GO term analysis, significant DEGs between I-MSCs and MSCs derived from jaw bone (Mx-/Md-MSCs) were selected in order of the largest fold change. The top 20 up-regulated DEGs in I-MSCs compared with Mx- or Md-MSCs revealed that most genes specifically expressed in I-MSCs were from the HOX gene family although *WISP3* was also specifically expressed in I-MSCs (Tables 1 and 2).

Next, we further evaluated the expression profile of all HOX genes among the three samples. We obtained HOX FPKM values, and analyzed the degree and distribution of HOX gene expression levels (Supplemental Figures 2A and 2B). I-MSCs were found to have a HOX-positive profile, while MSCs derived from jaw bones (Mx-/Md-MSCs) had HOX-negative profiles. To investigate the gene expression profiles of other cell types, we obtained RNA-seq data from human embryonic stem cells (ESCs), human ESC-derived MSCs (ES-MSCs), and human bone marrow-derived MSCs (BM-MSCs) from the Sequence Reads Archive (DDBJ accession number: SRA245478) and previous RNA-seq data owned by Tokyo Women’s Medical University (TWMU) from human periodontal ligament-derived MSCs (PDL-MSCs), BM-MSCs (TWMU-BMMSCs), and BM-MSCs cultured in ODM (ODMSCs). Figure 4a and 4b show that ESCs and PDL-MSCs also possessed a HOX-negative profile, similar to Mx- and Md-MSCs. Interestingly, although ESCs had a HOX-negative profile, the expression patterns of HOX genes changed to HOX-positive after the cells differentiated into MSCs. There was less change in the expression profile of HOX genes between TWMU-BMMSCs and ODMSCs, suggesting that HOX mRNA expression may not be affected by ODM.

**Characteristics of gene expression patterns in different types of tissue-derived MSCs and ESCs.**

To investigate whether HOX-negative MSCs such as PDL-MSCs, Mx-MSCs, and Md-MSCs showed similar gene expression patterns, U-DEG and D-DEG mRNA expression was analyzed among nine samples. U-DEG and D-DEG expression patterns in PDL-MSCs were similar to those in Mx-/Md-MSCs, while U-DEG and D-DEG expression patterns in MSCs derived from bone marrow (BM-MSCs, TWMU-BMMSCs, and ODMSCs) and ES-MSCs were similar to those in I-MSCs (Supplemental Figures 3A and 3B). These results revealed the similarity of HOX-negative MSCs and the similarity of HOX-positive MSCs with respect to gene expression profiles in U-DEGs and D-DEGs.

Next, we investigated the specific up-regulated DEGs in maxillofacial region-derived MSCs (Mx-MSCs, Md-MSCs, and PDL-MSCs; Mfr-MSCs) compared with the others. We identified 8 genes with FPKM levels in each Mfr-MSC sample that were twice as high as in the other six samples: *MSX1, NCAM1, LHX8, BARX1, FOXF1, S100A4, ZNF185*, and *NPTX1* (Figure 5). The expression levels of *LHX8, BARX1, FOXF1, and NCAM1* were quite low (FPKM < 1.0) in non Mfr-MSCs, indicating that they could be used as specific marker genes for Mfr-MSCs.

**Gene expression profiles of CD antigens in each sample.**

Figure 6 shows the gene expression profile of each type of MSC and ESC. The mRNA expression of positive markers for MSCs, such as CD105, CD73, and CD44, was significantly higher (FPKM > 50) in all MSCs compared with ESCs (FPKM < 3.0). CD90, an MSC-positive marker, was highly expressed (FPKM > 100) in both MSCs and ESCs. The mRNA expression of MSC-negative markers, such as CD14, CD34, and CD45, showed low levels (FPKM < 2.0) in MSCs and ESCs. CD106 and CD270 were not expressed (FPKM = 0) in ESCs, although these genes demonstrated high or low expression in MSCs. The expression patterns of all CD antigen genes were similar among different type of MSCs, except for ESCs.

**Discussion**

Although several studies have suggested that MSCs can be isolated from various tissues, such cells have different *in vitro* characteristics such as proliferation abilities, differentiation potentials, and gene expression...
profiles [26, 27]. In the present study, I-MSCs readily differentiated into both osteoblasts and adipocytes; in contrast, Mx-MSCs and Md-MSCs, derived from bone of the maxillofacial region, hardly differentiated into adipocytes, and the osteogenic potential of Mx-MSCs was significantly lower than that of I-MSCs.

In support of this, alveolar BM-MSCs were previously found to show little differentiation into adipocytes and chondrocytes, in contrast to ilium BM-MSCs [29]. However, the differentiation potential and HOX genes profile of maxilla differ from those of the mandible, which may reflect the fact that Md-MSCs were isolated from bone tissue of the mandibular angle. Although the maxillofacial bone is usually formed by intramembranous ossification [30, 31], the condyle, coronoid, and angular of the mandible develop through endochondral ossification [32]. Therefore, cells in the mandibular angle have different characteristics to those in the maxilla even though they are both maxillofacial bone. RNA-seq findings of our study also showed a difference in gene expression profiles between Mx-MSCs and Md-MSCs, which should be studied further.

We focused our attention on gene expression profile among MSCs derived from maxillofacial bone of neural crest origin and iliac bone of mesoderm origin in RNA-seq data analysis. While these cells generally are classified as MSCs, the gene expression profiles, particularly the HOX gene family are greatly different. MSCs originating from the ilium were shown to be HOX-positive, while those originating from the maxillofacial bone were HOX-negative. This study had a limitation in that distribution of donor age among each type of MSCs was uneven. Since primary culture was performed using remaining bone tissue obtained from bone grafting in cleft lip and palate patients or osteotomy in jaw deformity patients, donor age was dependent on operation timing. However, our previous study showed that ALP activity of I-MSCs cultured in osteoinductive medium for one week was not different from that of Md-MSCs [33]. Therefore, it is quite likely that HOX genes profile of MSCs is not related to donor age. Furthermore, PDL-MSCs residing in the maxillofacial region were also HOX-negative. Interestingly, some researchers have suggested that human fibroblasts retain the memory of the embryonic HOX status both in vitro and in vivo [34, 35]. Therefore, MSCs may retain memory from the developmental process, whether the cells derived from neural crest or not.

Our findings are consistent with previous studies, which showed that the Hox status of tibiae was positive, while that of the mandibular was negative [28, 36]. Moreover, Matsubara et al. showed that alveolar bone marrow-derived MSCs hardly differentiated into chondrocytes compared with iliac bone marrow-derived MSCs [29], while Iwata et al. found that the chondrogenic differentiation capacity of PDL-MSCs was lower than that of adipose-derived or bone marrow-derived MSCs [37]. Thus, HOX-negative MSCs might be less prone to differentiate into chondrocytes compared with HOX-positive MSCs. Because the progenitor of HOX-negative maxillofacial bone typically forms bone via intramembranous ossification and does not follow the differentiation process into chondrocytes, it is assumed that MSCs originating from the same region may be programmed not to differentiate into chondrocytes. However, our RNA-seq data showed that several HOX genes were expressed in Md-MSCs, which therefore may not be completely HOX-negative despite the fact that the cells originated from maxillofacial bone. The cause of this discrepancy may reflect the characteristics of Md-MSCs isolated from the mandibular angle which develop through endochondral ossification. The results also suggest that the HOX gene cluster regulates the chondrogenic differentiation of MSCs.

Our RNA-seq data revealed that Mfr-MSCs were HOX-negative, and identified specifically up-regulated genes in Mfr-MSCs, including MSX1, NCAM1, LHX8, BARX1, FOXF1, S100A4, ZNF185, and NPTX1. A previous study identified severe craniofacial defects in Msx1−/− mice including the failure of palatal shelves to elevate and fuse, mandible and middle ear ossicle deformities, the absence of molars, and delayed ossification [38, 39]. Other research indicated that mutations in human MSX1 are associated with cleft palate and tooth agenesis [40, 41]. Additionally, a targeted Lhx8 mutation in mice caused cleft palate in around 60% of animals [42]. Moreover, the microdeletion of BARX1 in humans is associated with craniofacial developmental disorders such as microstomia and mandibular retraction [43], while BARX1 was recently shown to function as a direct downstream factor of GATA4 in neural crest development [44]. Hence, the Mfr-MSC-specific up-regulated genes obtained from our RNA-seq data may serve as key factors for neural crest or craniofacial bone (intramembranous ossification) development. In contrast, previous studies found that the ectopic expression of several Hox genes induced craniofacial and skeletal malformation in transgenic mice [45, 46]. Therefore, some Hox genes appear not to be expressed in the cranial region during development. These findings suggest that the maxillofacial region is regulated by different transcription factors to other regions during development, and it is inferred from our RNA-
seq data that MSCs inherit site-specific memories.

The International Society for Cellular Therapy (ISCT) proposed sets of minimum criteria to identify MSCs [47]. In fact, our RNA-seq data revealed similar expression patterns of specific cell surface marker genes among each type of MSCs, except for ESCs. Moreover, despite differences in the differentiation capacity among MSC types, these cells nevertheless possessed a multilineage differentiation ability. Therefore, although cells that fulfill the minimum ISCT criteria are categorized as the same MSCs, it may be more effective to use MSCs derived from the same tissue for cell therapy considering that they inherit the characteristics of the tissue of origin. Indeed, adipose-derived MSCs possessed a high potential for adipogenesis [48], while cartilage-derived MSCs had a high potential for chondrogenesis in an in vitro assay [49]. In in vivo studies, PDL-MSCs showed the greatest potential to regenerate periodontal ligament tissue compared with other sources of MSCs [50]. Considering the varied characteristics of MSCs, it is important to carefully consider the most suitable source for the regeneration therapy of target tissue.

Conclusions

In this study, Mx / Md-MSCs were shown to have a different gene expression profile compared to I-MSCs, based on RNA-sequencing. In particular, since HOX status of MSCs originating from oral and maxillofacial tissues was HOX-negative, the expression patterns of HOX genes are quite different whether the cells derived from over the neck or not. Although stromal cells from different anatomical sources are generally categorized as MSCs, their differentiation potential and biological functions vary. Our findings suggest that MSCs may retain an original tissue memory about the developmental process, including gene expression profiles. This could have an important impact when choosing an appropriate cell source for regenerative therapy using MSCs.

Methods

Specimens and cell cultures

Nine bone specimens (ilium: three cases, maxilla: three cases, mandible: three cases; Supplemental Table S1), harvested during conventional surgery conducted by the Department of Plastic and Aesthetic Surgery at Kitasato University, were used in the present study. Table S1 shows patient profiles, including sex, age, and type of bone. Small pieces of bone were prepared and subjected to primary culture in complete medium containing 10% fetal bovine serum (MP Biomedicals LLC, Santa Ana, CA) at 37°C with 95% humidity and 5% CO₂. The complete medium consisted of alpha-minimum essential medium (Thermo Fisher Scientific, Waltham, MA), 100 U/mL penicillin and 100 µg/mL streptomycin (Thermo Fisher Scientific), and 1 ng/mL basic fibroblast growth factor (R&D Systems, Minneapolis, MN). The medium was changed twice a week. At confluency, MSCs were separated and harvested using 0.05% trypsin-EDTA (Thermo Fisher Scientific). Second and third passage MSCs were used in this study.

Differentiation for osteogenesis and adipogenesis

MSCs were cultured to confluence in complete medium, then seeded in 6-well plates at a density of $1 \times 10^5$ cells/well. Osteogenic differentiation was induced by culturing in osteogenic differentiation medium (ODM), consisting of complete medium supplemented with 100 nM dexamethasone (Sigma-Aldrich, St Louis, MO), 0.05 mM ascorbic acid (Wako Pure Chemical Industries, Osaka, Japan), and 10 mM β-glycerophosphate (Calbiochem, San Diego, CA). Cells were grown at 37°C with 5% CO₂. The medium was replaced twice a week.

Adipogenic differentiation occurred in adipogenic differentiation medium (ADM), consisting of complete medium supplemented with 1 µM dexamethasone, 0.01 mg/ml insulin (Wako Pure Chemical Industries), 0.2 mM indomethacin (Wako Pure Chemical Industries), and 0.5 mM isobutylmethylxanthine (Sigma-Aldrich). The medium was replaced twice a week.
Chondrogenic differentiation was performed according to the pellet culture method [51]. Briefly, $2 \times 10^5$ cells were transferred to a 15-mL polypropylene tube and centrifuged at 1,000 rpm for 5 minutes at 20°C to obtain a pellet. After at least 24 hours, the cells were subjected to differentiation induction using chondrogenic differentiation medium (CDM), consisting of High-glucose DMEM (Gibco) supplemented with 2mM L-glutamine (MP Biomedicals), 10 ng/mL human recombinant TGF-β1 (Sigma-Aldrich), 100 nM dexamethasone, 50 μg/mL ascorbic acid-2-phosphate, 100 μg/mL sodium pyruvate, and 50 mg/mL ITS+Premix (Corning). The medium was replaced twice a week.

**Examination and evaluation of MSC characteristics**

For osteogenic differentiation, MSCs were cultured in ODM at 37°C and 5% CO$_2$ for 6 weeks. The ODM was replaced twice a week. For adipogenic differentiation, MSCs were cultured in ODM for 3 weeks. After culturing for 3 weeks, the medium was changed to ADM, and MSCs were cultured for an additional 3 weeks. As a control, MSCs were continuously cultured in ODM for 6 weeks.

For the calcium (Ca) production assay, MSCs were seeded at $1 \times 10^5$ cells/well in 6-well plates and cultured in ODM or complete medium (negative control) at 37°C under 5% CO$_2$. ODM and complete medium were replaced twice a week. Samples were collected at 4 and 6 weeks after osteogenic differentiation. ESPA Ca (Nipro, Osaka, Japan) was used to assay Ca levels.

For Ca staining with the alizarin red S staining assay, MSCs were seeded at $1 \times 10^5$ cells/well in 6-well plates and cultured in ODM or complete medium at 37°C under 5% CO$_2$. ODM and complete medium were replaced twice a week. Alizarin red S staining was conducted 6 weeks after osteogenic differentiation by staining MSCs for 2 min with 1.3% alizarin red S solution at room temperature, washing twice with phosphate-buffered saline (PBS), fixing with 100% ethanol, and washing twice with distilled water. The excess staining solution was removed by washing three times with distilled water, then the cells were allowed to dry.

For lipid staining with oil red O solution, MSCs were cultured in ODM at 37°C under 5% CO$_2$. ODM was replaced twice a week. After culturing for 3 weeks, the medium was changed to ADM, and MSCs were cultured for 3 weeks further. As a control, MSCs were continuously cultured for 6 weeks in ODM. Oil red O staining was performed after adipogenic differentiation by washing cells twice with PBS, fixing with 10% formalin, washing once with distilled water then once with 60% isopropanol, and staining for 20 min in oil red O solution. Cells were then washed once each with 60% isopropanol and distilled water.

The chondrogenic differentiation potency was evaluated after 3 weeks culture in CDM. The chondrocyte mass was washed twice with PBS and fixed with 4% PFA overnight at 4°C. After paraffin embedding, the specimen block was cut into 5µm sections and stained with toluidine blue (Wako Pure Chemical Industries).

**Isolation of total RNA and cDNA library preparation for RNA-sequencing (RNA-seq)**

For RNA-seq, ilium-derived MSCs (I-MSCs), maxilla-derived MSCs (Mx-MSCs), and mandible-derived MSCs (MdMSCs) were seeded in 100 mm dishes at a density of $5 \times 10^5$ cells/dish and cultured in complete medium for 3 days. Total RNA was isolated using the RiboPure RNA Purification Kit (Thermo Fisher Scientific). The RNA integrity number score of every sample used for RNA-seq was >9. Strand-specific RNA libraries were constructed using the Dynabeads mRNA DIRECT Micro Purification Kit and the Ion Total RNA-Seq Kit v2.0 (Thermo Fisher Scientific). RNA-seq templates were prepared with the Ion PI Hi-Q OT2 200 Kit using the Ion OneTouch 2 and Ion OneTouch ES systems (Thermo Fisher Scientific). These templates were loaded onto Ion PI Chips and sequenced on the Ion Proton Sequencer using the Ion PI Hi-Q Sequencing 200 Kit (Thermo Fisher Scientific).

**Statistical and bioinformatics analysis**

Adaptor sequences on raw reads for each sample were removed by Cutadapt (v. 1.10), and low-quality bases were trimmed by Trimmomatic (v. 0.35). Sequencing reads were aligned to the human reference genome (hg19) using Bowtie2 (v. 2.2.6)/Tophat2 (v. 2.1.0) software [52]. Uniquely mapped reads were normalized to gene expression as fragments per kilobase of exon per million mapped fragments (FPKM) using Cufflinks (v. 2.2.1).
packages (Tophat2-Cufflinks pipeline [53]). To detect differentially expressed genes (DEGs) between two samples, we used Cuffdiff that generates a fold change for every gene, a \( p \)-value, and the false discovery rate with the Benjamini-Hochberg correction \( (q\text{-value}) \) in the Cufflinks packages. DEGs were defined when the \( q \)-value < 0.05 and the fold change of FPKM was \( \geq 2.0 \). The human reference genome and the Refseq annotation were downloaded from the UCSC Genome Browser (https://genome.ucsc.edu/). Enriched Gene Ontology (GO) terms were analyzed using the Database for Annotation, Visualization and Integrated Discovery (DAVID; https://david.ncifcrf.gov/) with the annotation dataset GO biological process. Specific GO terms were obtained from the NCBI database (ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/). Most of the data were corrected and calculated by custom Perl scripts. Plots and graphs obtained from RNA-seq analysis were visualized using ggplot2 and other R packages. Clustering analysis was conducted by the function hclust of R. RNA-seq datasets generated in this study have been deposited in the DNA Data Bank of Japan (DDBJ) Sequence Read Archive under accession numbers DRA006607–006615. In the statistical analyses for Ca content assay, all of the values are reported as the mean \( \pm \) standard deviation (SD). Tukey’s HSD test was performed for comparing differences between multiple groups. Differences were considered significant at \( p < 0.05 \).

### Abbreviations

**MSCs:** Multipotent mesenchymal stromal cells  
**I-MSCs:** Ilium-derived MSCs  
**Mx-MSCs:** Maxilla-derived MSCs  
**Md-MSCs:** Mandibular-derived MSCs  
**ODM:** Osteogenic differentiation medium  
**OD-MSCs:** BM-MSCs cultured in ODM  
**PDL-MSCs:** Periodontal ligament-derived MSCs  
**ESCs:** Embryonic stem cells  
**ES-MSCs:** ESC-derived MSCs  
**Mfr-MSCs:** Maxillofacial region-derived MSCs  
**RNA-seq:** RNA-sequencing  
**FPKM:** fragments per kilobase of exon per million mapped fragments  
**MΦ:** macrophage  
**U-DEGs:** Up-regulated DEGs in I-MSCs compared with Mx- and Md-MSCs  
**D-DEGs:** Down-regulated DEGs in I-MSCs compared with Mx- and Md-MSCs
Table 1
The top 20 up-regulated DEGs in I-MSCs compared with Mx-MSCs

| Gene      | FPKM (Mean) | FC (log2) |
|-----------|-------------|-----------|
| HOXC6 ↑   | 30.353      | < 0.0001  | 18.211   |
| HOXC10 ↑  | 22.068      | < 0.0001  | 17.752   |
| HOXC8 ↑   | 12.962      | < 0.0001  | 16.984   |
| HOXB4 ↑   | 12.954      | < 0.0001  | 16.983   |
| HOXC9 ↑   | 12.075      | < 0.0001  | 16.882   |
| HOXA3 ↑   | 1.255       | < 0.0001  | 16.487   |
| HOXA11 ↑  | 2.189       | < 0.0001  | 14.912   |
| HOXD4 ↑   | 2.538       | < 0.0001  | 14.631   |
| HOXA7 ↑   | 3.083       | < 0.0001  | 14.528   |
| HOXA4 ↑   | 7.18        | < 0.0001  | 14.347   |
| HOXC-AS1 ↑| 2.084       | < 0.0001  | 14.345   |
| HOXC-AS2 ↑| 2.071       | < 0.0001  | 14.338   |
| HOXC6 + § | 30.353      | 0.214447  | 7.145    |
| CACNG8 + §| 10.729      | 0.145148  | 6.208    |
| HOXC9 + § | 12.075      | 0.28332   | 5.281    |
| CELSR3 +  | 7.617       | 0.23098   | 5.093    |
| CH3L1 +   | 18.989      | 0.494379  | 5.033    |
| ROR2 +    | 1.729       | 0.0724027 | 4.577    |
| HIST1H2BH | 13.291      | 0.606649  | 4.454    |
| UNC5C +   | 1.071       | 0.0503351 | 4.412    |
| TENM2 +   | 1.548       | 0.0745513 | 4.376    |
| HOXA11 +  | 2.189       | 0.106172  | 4.366    |

†: HOX gene family, §: non-coding RNAs, FC: Fold change of FPKM value between two samples (log2 of FC)

Table 2
The top 20 up-regulated DEGs in I-MSCs compared with Md-MSCs

| Gene      | FPKM (Mean) | FC (log2) |
|-----------|-------------|-----------|
| VTRNA1-1 §| 336.731     | < 0.0001  | 21.693   |
| HOXC10 ↑  | 22.068      | < 0.0001  | 17.752   |
| HOXA1 ↓   | 2.363       | < 0.0001  | 14.528   |
| HOXA4 ↑   | 2.084       | < 0.0001  | 14.347   |
| HOXA-AS2 ↑| 2.081       | < 0.0001  | 14.345   |
| HOXC-AS2 ↑| 1.64        | < 0.0001  | 14.001   |
| HOXC11 ↑  | 1.627       | < 0.0001  | 13.99    |
| HLA-DQB1  | 0.81        | < 0.0001  | 13.982   |
| HOXA6 + § | 4.767       | < 0.0001  | 13.616   |
| HOXA-AS2  | 2.081       | < 0.0001  | 13.366   |
| WISP3 +   | 1.548       | < 0.0001  | 13.331   |
| HOXA1 ↑   | 1.548       | < 0.0001  | 12.984   |
| HOTAIRM1 ↑| 9.188       | < 0.0001  | 12.278   |

†: HOX gene family, §: non-coding RNAs, FC: Fold change of FPKM value between two samples (log2 of FC)
Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee at Tokyo Women’s Medical University (approval number: 4155) and Kitasato University (approval number: B12-53) that examines the use of tissues of human cell origin, and was conducted after the acquisition of written informed consent from patients or their families.

Consent for publication

Not applicable

Availability of data and materials

RNA-seq data generated and analyzed in this study have been deposited in the DNA Data Bank of Japan (DDBJ) Sequence Read Archive under accession numbers DRA006607–006615. The scripts and materials are available from the corresponding author on reasonable requests.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported by the Japan Agency for Medical Research and Development (Grant number 17be0104010h0002) and the Japan Society for the Promotion of Science (KAKENHI Grant Number 17K17219). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors’ contributions

SO, YY, and TI designed and conceived the project. SO and SJP analyzed the RNA-seq data. YY, TS, and YS designed and carried out in vitro experiments, and analyzed the data. SO, YY, and TI wrote the manuscript. SS, MU, AT, KNakai, and KNakashima contributed to data processing, discussions and advice and reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The super-computing resource was provided by the Human Genome Center, the Institute of Medical Science, and the University of Tokyo (http://sc.hgc.jp/shirokane.html). We thank Sarah Williams, Ph.D., from Edanz Group (www.edanzediting.com) for editing a draft of this manuscript.

Authors’ information

Affiliations

Division of Periodontology, Department of Oral Function, Kyushu Dental University, Fukuoka, 803-8580, Japan
Satoru Onizuka, Michihiko Usui & Keisuke Nakashima

Department of Plastic and Aesthetic Surgery, Kitasato University School of Medicine, Kanagawa, 252-0374, Japan
Yasuharu Yamazaki, Takayuki Sugimoto, Yumiko Sone & Akira Takeda

Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8693, Japan
Sung-Joon Park & Kenta Nakai
Institute of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University, Tokyo, 162-8666, Japan

Sebastian Sjöqvist

Department of Periodontology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan

Takanori Iwata

Corresponding author

Correspondence to Takanori Iwata

References

1. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. *Science* 1997, 276(5309):71-74.

2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. *science* 1999, 284(5411):143-147.

3. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH: Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell* 2002, 13(12):4279-4295.

4. De Bari C, Dell’Accio F, Vanlauwe J, Eyckmans J, Khan IM, Archer CW, Jones EA, McGonagle D, Mitsiadis TA, Pitzalis C et al: Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis. *Arthritis Rheum* 2006, 54(4):1209-1221.

5. Trubiani O, Orsini G, Zini N, Di Iorio D, Piccirilli M, Piattelli A, Caputi S: Regenerative potential of human periodontal ligament derived stem cells on three-dimensional biomaterials: a morphological report. *J Biomed Mater Res A* 2008, 87(4):986-993.

6. Onizuka S, Iwata T, Park SJ, Nakai K, Yamato M, Okano T, Izumi Y: ZBTB16 as a Downstream Target Gene of Osterix Regulates Osteoblastogenesis of Human Multipotent Mesenchymal Stromal Cells. *J Cell Biochem* 2016, 117(10):2423-2434.

7. Caplan Al, Correa D: The MSC: an injury drugstore. *Cell Stem Cell* 2011, 9(1):11-15.

8. Short BJ, Brouard N, Simmons PJ: Prospective isolation of mesenchymal stem cells from mouse compact bone. In: *Stem Cells in Regenerative Medicine*. Springer; 2009: 259-268.

9. Yamachika E, Tsujigiwa H, Matsubara M, Hirata Y, Kita K, Takabatake K, Mizukawa N, Kaneda Y, Nagatsuka H, Iida S: Basic fibroblast growth factor supports expansion of mouse compact bone-derived mesenchymal stem cells (MSCs) and regeneration of bone from MSC in vivo. *Journal of molecular histology* 2012, 43(2):223-233.

10. Nk M, Cy T, U B, ClI C, Eh W, Is P, T S: Investigating Cell Surface Markers and Differentiation Potential of Compact Bone-Derived Mesenchymal Stem Cells. *International Journal of Stem Cell Research and Transplantation* 2015:91-95.

11. García-Gareta E, Coathup MJ, Blunn GW: Osteoinduction of bone grafting materials for bone repair and regeneration. *Bone* 2015, 81:112-121.

12. Sakkas A, Wilde F, Heufelder M, Winter K, Schramm A: Autogenous bone grafts in oral implantology—is it still a “gold standard”? A consecutive review of 279 patients with 456 clinical procedures. *International journal of implant dentistry* 2017, 3(1):23.

13. Eufinger H, Leppänen H: Iliac crest donor site morbidity following open and closed methods of bone harvest for alveolar cleft osteoplasty. *Journal of Cranio-Maxillo-Facial Surgery* 2000, 28(1):31-38.

14. Boyne PJ: Secondary bone grafting of residual alveolar and palatal clefts. *J Oral Surgery* 1972, 30:87-92.

15. Bajaj AK, Wongworawat AA, Punjabi A: Management of alveolar clefts. *Journal of Craniofacial Surgery*
16. Swan MC, Goodacre TE: Morbidity at the iliac crest donor site following bone grafting of the cleft alveolus. Br J Oral Maxillofac Surg 2006, 44(2):129-133.

17. Kinoshita Y, Maeda H: Recent developments of functional scaffolds for craniomaxillofacial bone tissue engineering applications. The Scientific World Journal 2013, 2013.

18. Dickinson BP, Ashley RK, Wasson KL, O’Hara C, Gabbay J, Heller JB, Bradley JP: Reduced morbidity and improved healing with bone morphogenic protein-2 in older patients with alveolar cleft defects. Plastic and Reconstructive Surgery 2008, 121(1):209-217.

19. Nussenbaum B, Krebsbach PH: The role of gene therapy for craniofacial and dental tissue engineering. Advanced drug delivery reviews 2006, 58(4):577-591.

20. Chang SC, Chuang H, Chen YR, Yang LC, Chen JK, Mardini S, Chung HY, Lu YL, Ma WC, Lou J: Cranial repair using BMP-2 engineered bone marrow stromal cells. J Surg Res 2004, 119(1):85-91.

21. Krebsbach PH, Mankani MH, Satomura K, Kuznetsov SA, Robey PG: Repair of craniotomy defects using bone marrow stromal cells. Transplantation 1998, 66(10):1272-1278.

22. Mankani MH, Kuznetsov SA, Wolfe RM, Marshall GW, Robey PG: In vivo bone formation by human bone marrow stromal cells: reconstruction of the mouse calvarium and mandible. Stem Cells 2006, 24(9):2140-2149.

23. Gimbel M, Ashley RK, Sisodia M, Gabbay JS, Wasson KL, Heller J, Wilson L, Kawamoto HK, Bradley JP: Repair of alveolar cleft defects: reduced morbidity with bone marrow stem cells in a resorbable matrix. Journal of Craniofacial Surgery 2007, 18(4):895-901.

24. Noden DM: Patterns and organization of craniofacial skeletogenic and myogenic mesenchyme: a perspective. Progress in clinical and biological research 1982, 101:167-203.

25. Couly GF, Coltey PM, Le Douarin NM: The triple origin of skull in higher vertebrates: a study in quail-chick chimeras. Development 1993, 117(2):409-429.

26. Hass R, Kasper C, Böhm S, Jacobs R: Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Communication and Signaling 2011, 9(1):12.

27. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W et al: Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005, 33(11):1402-1416.

28. Leucht P, Kim JB, Amasha R, James AW, Girod S, Helms JA: Embryonic origin and Hox status determine progenitor cell fate during adult bone regeneration. Development 2008, 135(17):2845-2854.

29. Matsubara T, Suardita K, Ishii M, Sugiyama M, Igarashi A, Oda R, Nishimura M, Saito M, Nakagawa K, Yamanaka K et al: Alveolar bone marrows as a cell source for regenerative medicine: differences between alveolar and iliac bone marrow stromal cells. J Bone Miner Res 2005, 20(3):399-409.

30. Bronner ME, LeDouarin NM: Development and evolution of the neural crest: an overview. Dev Biol 2012, 366(1):2-9.

31. Chai Y, Maxson RE, Jr: Recent advances in craniofacial morphogenesis. Dev Dyn 2006, 235(9):2353-2375.

32. Oka K, Oka S, Hosokawa R, Bringas P Jr., Brockhoff HC, Nonaka K, Chai Y: TGF-beta mediated Dlx5 signaling plays a crucial role in osteo-chondroprogenitor cell lineage determination during mandible development. Dev Biol 2008, 321(2):303-309.

33. Matsuo A, Yamazaki Y, Takase C, Aoyagi K, Uchinuma E: Osteogenic potential of cryopreserved human bone marrow-derived mesenchymal stem cells cultured with autologous serum. J Craniofac Surg 2008, 19(3):693-700.

34. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, Brown PO: Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA 2002, 99(20):12877-12882.

35. Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY: Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS Genet 2006, 2(7):e119.

36. Wang KC, Helms JA, Chang HY: Regeneration, repair and remembering identity: the three Rs of Hox gene expression. Trends Cell Biol 2009, 19(6):268-275.
37. Iwata T, Yamato M, Zhang Z, Mukobata S, Washio K, Ando T, Feijen J, Okano T, Ishikawa I: Validation of human periodontal ligament-derived cells as a reliable source for cytotherapeutic use. J Clin Periodontol 2010, 37(12):1088-1099.
38. Satokata I, Maas R: Msx1 deficient mice exhibit cleft palate and abnormalities of craniofacial and tooth development. Nature genetics 1994, 6(4):348.
39. Alappat S, Zhang ZY, Chen YP: Msx homeobox gene family and craniofacial development. Cell research 2003, 13(6):429.
40. Vastardis H, Karimbux N, Guthua SW, Seidman J, Seidman CE: A human MSX1 homeodomain missense mutation causes selective tooth agenesis. Nature genetics 1996, 13(4):417.
41. van den Boogaard MJ, Dorland M, Beemer FA, van Amstel HK: MSX1 mutation is associated with orofacial clefting and tooth agenesis in humans. Nat Genet 2000, 24(4):342-343.
42. Zhao Y, Guo Y-J, Tomac AC, Taylor NR, Grinberg A, Lee EJ, Huang S, Westphal H: Isolated cleft palate in mice with a targeted mutation of the LIM homeobox gene lhx8. Proceedings of the National Academy of Sciences 1999, 96(26):15002-15006.
43. Redon R, Baujat G, Sanlaville D, Le Merrer M, Vekemans M, Munnich A, Carter NP, Cormier-Daire V, Colleaux L: Interstitial 9q22.3 microdeletion: clinical and molecular characterisation of a newly recognised overgrowth syndrome. Eur J Hum Genet 2006, 14(6):759-767.
44. Guo S, Zhang Y, Zhou T, Wang D, Weng Y, Chen Q, Ma J, Li YP, Wang L: GATA4 as a novel regulator involved in the development of the neural crest and craniofacial skeleton via Barx1. Cell Death Differ 2018.
45. Balling R, Mutter G, Gruss P, Kessell M: Craniofacial abnormalities induced by ectopic expression of the homeobox gene Hox-1.1 in transgenic mice. Cell 1989, 58(2):337-347.
46. McLain K, Schreiner C, Yager KL, Stock JL, Potter SS: Ectopic expression of Hox-2.3 induces craniofacial and skeletal malformations in transgenic mice. Mechanisms of development 1992, 39(1-2):3-16.
47. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8(4):315-317.
48. Peng L, Jia Z, Yin X, Zhang X, Liu Y, Chen P, Ma K, Zhou C: Comparative analysis of mesenchymal stem cells from bone marrow, cartilage, and adipose tissue. Stem Cells Dev 2008, 17(4):761-773.
49. Tsumanuma Y, Iwata T, Washio K, Yoshida T, Yamada A, Takagi R, Ohno T, Lin K, Yamato M, Ishikawa I: Comparison of different tissue-derived stem cell sheets for periodontal regeneration in a canine 1-wall defect model. Biomaterials 2011, 32(25):5819-5825.
50. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH: Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004, 103(5):1669-1675.
51. Trapnell C, Pachter L, Salzberg SL: TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009, 25(9):1105-1111.
52. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L: Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012, 7(3):562-578.
Figure 1

Differentiation potential of each type of bone-derived MSCs. a Alizarin red S staining of MSCs cultured in ODM or complete medium for 6 weeks. –, MSCs cultured in complete medium for 6 weeks; +, MSCs cultured in ODM for 6 weeks. b Oil red O staining of MSCs cultured in ADM or ODM for 6 weeks. –, MSCs cultured in ODM for 6 weeks; +, MSCs cultured in ODM for 3 weeks, then in ADM for 3 weeks. c Toluidine blue staining of MSCs cultured in CDM or complete medium for 3 weeks. –, MSCs cultured in complete medium for 3 weeks; +, MSCs cultured in ODM for 3 weeks. These images show the representative data from three different samples; a similar tendency was observed in other MSCs. d Calcium was produced when MSCs were cultured in ODM for 4 and 6 weeks. Bars represent the mean ± S.D. of triplicate samples. Asterisks denote significant difference (p < 0.05, Tukey’s HSD)
Figure 2

Gene expression profile and GO term enrichment analysis of bone-derived MSCs. a Cumulative number (left) and ratio (right) of single-ended reads generated from the Ion Proton system (1e+07 = 10,000,000). b Cumulative number (left) and ratio (right) of sequencing reads aligned to the human reference genome (hg19). Each color represents a different RNA biotype, such as protein-coding RNA, non-coding RNA, and unknown. ‘modified_data’ is Refseq genes expressed in at least one group with FPKM ≥1. c The expression levels of CD14, CD45, CD73, CD90, and CD105 among each type of cells. The RNA-seq data (accession number: SRA245718) of human Macrophage (MΦ) were used as control. d Heatmap showing the relative expression profile of 12,676 genes.
(FPKM ≥1) among I-MSCs, Mx-MSCs, and Md-MSCs. Scaled expression values are color-coded according to the legend on the left. These genes were categorized into 10 patterns by a hierarchical clustering approach. The genes in each pattern were over-represented by specific GO biological process terms (q < 0.05).

Figure 3
Profile of specific differentially expressed genes (DEGs) and GO term enrichment analysis using the DEGs. a Volcano plot showing all profiled genes. Gray and red circles represent non-DEGs and DEGs, respectively. Statistical analysis detected DEGs between two samples using a threshold (q-value <0.05 and a more than two-fold change in FPKM). b, c High (b) and low (c) expressed DEGs in I-MSCs compared with Mx / Md-MSCs. Venn
diagram shows the number of DEGs in I-MSCs vs. Mx-MSCs (yellow circle) and I-MSCs vs. Md-MSCs (blue circle). Bar plot shows the top 10 enriched GO terms identified from co-DEGs (mid area in the Venn diagram) using statistical analysis (horizontal axis represents -log10(q-value)). Red stars indicate the GO term involved in development.

Figure 4
Gene expression profile of all HOX genes among MSCs and ESCs. a Heat map showing the degree of expression levels (log2 of FPKM value) of all HOX genes. b Box plot showing the distribution of expression levels (log2 of FPKM value) of HOX genes (except HOX genes with FPKM = 0 in all samples). ESCs, human embryonic stem cells; ES-MSCs, human ESC-derived MSCs; BM-MSCs, human bone marrow-derived MSCs; TWMU-BMMSCs, BM-MSCs owned by TWMU; ODMSCs, TWMU-BMMSCs cultured with ODM; PDL-MSCs, periodontal ligament-derived MSCs.
Figure 5
Specific up-regulated DEGs in oral and maxillofacial tissue-derived MSCs. The vertical axis represents gene expression levels with log2 of [FPKM + 1]
Gene expression profile of CD molecules in each sample. Heatmap showing the degree of expression levels (log2 of FPKM value) of all CD genes. Scaled expression values are color-coded according to the legend on the left. Genes are hierarchically clustered by the similarity of their expression profiles over the set of samples, and the samples are hierarchically clustered by the similarity of expression patterns over their expression profile. The described genes (right side of heatmap) are representative CD molecules. Red letters represent positive markers for MSCs, and blue letters represent negative markers for MSCs.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1new.docx
- Additionalfile2.docx